China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
91 hedge funds and large institutions have $1.36B invested in China Biologic Products Holdings, Inc. in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 11 closing their positions.
773% more call options, than puts
Call options by funds: $21.1M | Put options by funds: $2.42M
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
8% more funds holding
Funds holding: 84 → 91 (+7)
5% more capital invested
Capital invested by funds: $1.29B → $1.36B (+$66.7M)
7% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 30
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCMGA
York Capital Management Global Advisors
New York
|
+$53.1M |
| 2 |
Renaissance Technologies
New York
|
+$39.8M |
| 3 |
AC
Athos Capital
Hong Kong
|
+$27.5M |
| 4 |
Temasek Holdings
Singapore
|
+$26.8M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$25.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BP
BFAM Partners
Northpoint, Hong Kong,
Hong Kong
|
-$13.7M |
| 2 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$13.1M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$12.9M |
| 4 |
MAM
Myriad Asset Management
North Point,
Hong Kong
|
-$12.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.8M |
CBPO Hedge Fund Activity: Q2 2020 in Review
91 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2020, worth a combined $1.36B — up 5.2% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CBPO positions and 11 closed out — a net gain of 8 holders — while 32 added to existing stakes and 30 trimmed.
The largest buyer was York Capital Management Global Advisors, adding an estimated $53.1M. The largest seller was BFAM Partners, exiting entirely with an estimated $13.7M sold.
- 91 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2020, up from 84 in Q1 2020.
- Funds reported $1.36B of China Biologic Products Holdings, Inc. stock for Q2 2020, up 5.2% quarter-over-quarter.
- 19 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2020 and 11 closed out, a net change of +8 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q2 2020 was York Capital Management Global Advisors, an estimated $53.1M added.
- The largest China Biologic Products Holdings, Inc. seller in Q2 2020 was BFAM Partners, an estimated $13.7M sold.
Based on aggregated 13F filings for Q2 2020.